Implantable arterial port-related bloodstream infection in patients with primary or metastatic hepatic malignancies

摘要

The incidence of implantable arterial post-related bloodstream infections (IAP-RBSI) among patients with unresectable hepatic malignancies is not well defined. We reviewed the 9-year incidence of implantable arterial post-related bloodstream infections in patients with hepatic malignancies, at a tertiary care center in Japan. The incidence was 1.9 infections per 10,000 catheter-days. Hepatic malignancies including primary (ie, hepatocellular carcinoma; HCC) and metastatic tumors cause substantial mortality. Although intrahepatic infusion of chemotherapeutic agents via an implanted arterial port has been used for treating unresectable HCC or hepatic metastases, the incidence of implantable arterial port-related bloodstream infections (IAP-RBSI) has not been previously examined. We reviewed the incidence of IAP-RBSI in patients with hepatic malignancies.